« Return to News | Drug Sponsors

Ipsen to relocate headquarters to New Jersey

Wednesday, April 25, 2012 10:59 AM

Ipsen, a global specialty-driven pharmaceutical company, has decided to open new commercial headquarters in Basking Ridge, N.J.

The move is an important step forward for Ipsen in the U.S., after the significant investment in its Mass.-based facility focused on R&D and technical operations (notably bioproduction) and the recently announced completion of its U.S. Leadership Team for commercial operations.

Relocation of the company’s headquarters is expected to create more than 100 new full-time jobs in New Jersey where the growing pharmaceutical and biopharmaceutical industries were key factors in Ipsen’s decision to establish U.S. headquarters in the state.

“For Ipsen, the U.S. is a new market in which we see significant opportunity. The move to New Jersey gives us access to the best talents of the biopharma industry, critical to Ipsen’s growth,” said Marc de Garidel, chairman and CEO of Ipsen.

Garidel added that the new headquarters “conveys our commitment to provide care to patient communities in the U.S., and will enable us to expand Ipsen’s capabilities and capacity in the U.S. marketplace for our specialty endocrine and neurology products.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.